within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG16_Rozanolixizumab;

model Rozanolixizumab
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 8.333333333333333e-08,
    adminDuration = 600,
    adminMass = 420 / 1000000,
    adminCount = 1,
    Vd = 0.0067,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0033,
    k12 = 1.1388888888888888e-07,
    k21 = 1.1388888888888888e-07);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Rozanolixizumab</td></tr><tr><td>ATC code:</td><td>L04AG16</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>420</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>6.7</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.3</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Rozanolixizumab is a humanized monoclonal antibody targeting the neonatal Fc receptor (FcRn), used for the treatment of generalized myasthenia gravis (gMG) in adults. It functions by reducing IgG levels and is approved for clinical use in several regions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were derived from clinical studies in adult patients with generalized myasthenia gravis following subcutaneous administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L04AG16 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Rozanolixizumab;
